ClinicalTrials.gg
CompletedNCT01808339Updated Jan 9, 2017Results posted

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

A Phase 2 interventional study of Fluticasone Furoate (FF) and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
29th of 40
28 · median 102
Started
2013
the only one that year
Phase 2
12 of 40
none open now
Registered
25th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 29th largest by enrollment, is the only one that started in 2013, is one of 12 in phase 2, and was the 25th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with persistent bronchial asthma. This is a repeat-dose, double-blind, randomized, placebo-controlled, three-way crossover study to compare the effect of morning (AM) and evening (PM) dosing with FF 100 on lung function. Twenty-four male and female subjects with persistent bronchial asthma will be enrolled to ensure twenty evaluable subjects. The three treatments will be FF 100 AM (with placebo PM), FF 100 PM (with placebo AM) and matching placebo (AM and PM). All treatments will be administered for 14 (+/-2) days with 14 day run-in and 14 to 21 day washout periods. The total duration of the study will be approximately 13 to18 weeks for each subject.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Fluticasone Furoate, FF Inhalation Powder, morning dosing, evening dosing, efficacy, FEV1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects with a documented history of persistent asthma, with the exclusion of other significant pulmonary diseases (pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma).
  • Male or female between 18 and 70 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is:
  • Of non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy or defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use method, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  • Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotropin (hCG) test at screening and serum or urine hCG test prior to dosing and agrees to use one of the contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until completion of the follow up visit or has only same-sex partners, when this is her preferred and usual lifestyle.
  • All subjects must either be clinically stable on a low to mid dose inhaled (ICS) (with or without a short acting beta-2 receptor agonist [SABA]) such as Fluticasone Propionate (FP) 100 to250 mcg twice-daily (total daily dose 200 to 500 mcg) or equivalent, for at least 4 weeks preceding the screening visit or be clinically stable on a low dose ICS/ long acting beta-2 receptor agonist (LABA) combination, such as SERETIDE/ADVAIR 100/50 twice- daily or equivalent (administered either in combination or from separate inhalers), for at least 4 weeks preceding the screening visit. Higher ICS/LABA doses (i.e. equivalent to SERETIDE/ADVAIR 250/50 or 500/50) would not be acceptable. Subjects must refrain from using their LABA for at least 24 hour (h) prior to the screening visit
  • Subjects with a screening pre-bronchodilator >= 60 percent of predicted. Predicted values will be based upon National Health and Nutrition Examination Survey (NHANES III).
  • During the screening visit, subjects must demonstrate the presence of reversible airway disease, defined as an increase in FEV1 of >= 12.0 percent over baseline and an absolute change of >= 200 mL within 60 minutes following 4 inhalations of albuterol/salbutamol inhalation aerosol (or equivalent nebulized treatment with albuterol/salbutamol solution).
  • All subjects must be able to replace all their current asthma treatments with albuterol/salbutamol aerosol inhaler at screening for use as needed for the run-in period and throughout the duration of the study. Subjects on LABAs must also withhold this for at least 24 h prior to the screening visit. Subjects will therefore be on SABA alone for the duration of the study, and on SABA and FF during the FF treatment periods. Subjects must be able to withhold albuterol/salbutamol for at least 6 h prior to screening and study visits.
  • Subjects who are current non-smokers and who have a pack history of \<= 10 pack years. A subject may not have used inhaled tobacco products within the past 3 months (i.e., cigarettes, cigars or pipe tobacco).
  • Body weight >= 50 kilograms (kg) and (BMI) within the range 19.0 to29.9 kg/meter\^2 (inclusive)
  • Based on single or averaged duration corrected for heart rate by Fridericia's formula (QTcF) values of triplicate (ECGs) obtained over a brief recording period: QTcF \< 450 millisecond (msec); or QTcF \< 480 msec in subjects with Bundle Branch Block.
  • (AST) and Alanine aminotransferase (ALT) \< 2x (ULN), alkaline phosphatase and \<= 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Able to satisfactorily use the DPI

Inclusion Criteria for Randomisation to Treatment

  • Evening pre-dose FEV1 of >=60 percent of their predicted normal at Day 1
  • Daily diary compliance defined as completion of all AM daily diary data on >=4 of the last 7 consecutive days of the Run-in Period (not including the date of randomisation) and completion of all PM daily diary data on >=4 of the last 7 consecutive days of the Run-in Period (not including the date of randomisation)

Exclusion Criteria:

  • A history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any asthma exacerbation requiring oral corticosteroids within 12 weeks of screening or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.
  • A subject has any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study. The list of additional excluded conditions/diseases includes, but is not limited to the following: congestive heart failure, known aortic aneurysm, clinically significant coronary heart disease, clinically significant cardiac arrhythmia, stroke within 3 months of Visit 1, uncontrolled hypertension, recent or poorly controlled peptic ulcer, hematologic, hepatic, or renal disease (with the exception of Gilbert's syndrome or asymptomatic gallstones), immunologic compromise, current , tuberculosis (current or untreated), Cushing's disease, Addison's disease, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, recent history of drug or alcohol abuse.
  • Any adverse reaction including immediate or delayed to any beta 2 agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the DPI (i.e. lactose).
  • History of severe milk protein allergy.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
  • Use of prescription or non-prescription drugs including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • Subjects who have taken oral steroids within 12 weeks of the screening visit.
  • History of regular alcohol consumption within 6 months of the study defined as Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a 285 mL glass of full strength beer or 425 mL schooner of light beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.

Exclusion Criteria based upon diagnostic assessments

  • A subject will not be eligible if he/she has clinical visual evidence of oral candidiasis at screening.
  • Pregnant females as determined by positive serum hCG test at screening or by positive serum or urine hCG test prior to dosing.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
  • A positive pre-study drug/alcohol screen.
  • A positive test for (HIV) antibody. Other Criteria
  • Lactating females.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product (IP) within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • No subject is permitted to perform night shift work for 1 week prior to screening until completion of the study treatment periods.
  • Unwillingness or inability to follow the procedures outlined in the protocol.

Exclusion Criteria for Randomisation to Treatment

  • Resuming their asthma medication (excluding albuterol/salbutamol inhalation aerosol provided at screening).
  • Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Evidence of a severe exacerbation, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids between screening and Day 1.
  • Clinical visual evidence of oral candidiasis at Day 1.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    FF AM dose

    All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).

    Drug: Fluticasone Furoate (FF) · Drug: Placebo

  • Experimental
    FF PM dose

    All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).

    Drug: Fluticasone Furoate (FF) · Drug: Placebo

  • Placebo comparator
    Placebo

    All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).

    Drug: Placebo

Interventions

  • Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).

  • DrugPlacebo

    Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).

06

What researchers measure

Primary outcomes

  1. Weighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using site equipment (KoKo Pneumotach Spirometer). Weighted mean FEV1 was calculated using the Day 14 24-hour serial FEV1 measurements taken at 3, 6, 9, 12, 15, 18, 21, and 24 hours post-dose (measured in the evening of Day 15). At each time point, the highest of three technically acceptable measurements was recorded. FEV1 weighted mean was analyzed using a mixed effects analysis of a covariance model with fixed effect terms for treatment and period, participant Baseline, period Baseline, gender, and age as covariates, and participant as a random effect.

    Time frame: 24 hours post-PM dose on Day 14 of each treatment period (up to Study Day 105)

Secondary outcomes

  1. Pre-treatment AM and PM Trough FEV1 on Day 14 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using site equipment (KoKo Pneumotach Spirometer). FEV1 PM trough FEV1 values were the values taken pre-treatment on Day 14, and AM trough FEV1 values were the values taken pre-treatment on Day 15 in each treatment period; thus, there is only one value (pre-treatment record) per period for AM and PM trough.

    Time frame: Day 14 of each treatment period (up to Study Day 105)

  2. Number of Participants With Any Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were collected from the start of dosing with investigational product and until follow-up.

    Time frame: Up to 18 weeks

  3. Peak Expiratory Flow (PEF)

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. AM and PM pre-treatment PEF was measured throughout the study for the purposes of monitoring participants' asthma stability, and was measured from the start of the Run-in Period until completion of Treatment Period 3 (including during the washout periods), prior to study medication and/or any rescue albuterol/salbutamol inhalation aerosol use. The data collected were only assessed by the Investigator on an individual basis during the study and were not formally summarized or statistically analyzed; consequently, data are not reported.

    Time frame: Up to 18 weeks

07

Results

Posted Sep 4, 2014

Participant flow

Participants meeting eligibility criteria at the Screening visit entered a 2-week Run-in Period for Baseline safety evaluations and to obtain measures of asthma status.

Treatment Period 1 (14 Days)
Participant flow — Treatment Period 1 (14 Days)
MilestoneFF 100 µg AM /FF 100 µg PM/PlaceboFF 100 µg AM/Placebo/FF 100 µg PMFF 100 µg PM /FF 100 µg AM/PlaceboFF 100 µg PM /Placebo/FF 100 µg AMPlacebo/FF 100 µg AM/FF 100 µg PMPlacebo/FF 100 µg PM /FF 100 µg AM
Started444466
Completed434245
Not completed010221
Withdrew: Met protocol-defined stopping criteria000121
Withdrew: Withdrawal by subject010100
Washout Period 1 (14-21 Days)
Participant flow — Washout Period 1 (14-21 Days)
MilestoneFF 100 µg AM /FF 100 µg PM/PlaceboFF 100 µg AM/Placebo/FF 100 µg PMFF 100 µg PM /FF 100 µg AM/PlaceboFF 100 µg PM /Placebo/FF 100 µg AMPlacebo/FF 100 µg AM/FF 100 µg PMPlacebo/FF 100 µg PM /FF 100 µg AM
Started434245
Completed434245
Not completed000000
Treatment Period 2 (14 Days)
Participant flow — Treatment Period 2 (14 Days)
MilestoneFF 100 µg AM /FF 100 µg PM/PlaceboFF 100 µg AM/Placebo/FF 100 µg PMFF 100 µg PM /FF 100 µg AM/PlaceboFF 100 µg PM /Placebo/FF 100 µg AMPlacebo/FF 100 µg AM/FF 100 µg PMPlacebo/FF 100 µg PM /FF 100 µg AM
Started434245
Completed434245
Not completed000000
Washout Period 2 (14-21 Days)
Participant flow — Washout Period 2 (14-21 Days)
MilestoneFF 100 µg AM /FF 100 µg PM/PlaceboFF 100 µg AM/Placebo/FF 100 µg PMFF 100 µg PM /FF 100 µg AM/PlaceboFF 100 µg PM /Placebo/FF 100 µg AMPlacebo/FF 100 µg AM/FF 100 µg PMPlacebo/FF 100 µg PM /FF 100 µg AM
Started434245
Completed434245
Not completed000000
Treatment Period 3 (14 Days)
Participant flow — Treatment Period 3 (14 Days)
MilestoneFF 100 µg AM /FF 100 µg PM/PlaceboFF 100 µg AM/Placebo/FF 100 µg PMFF 100 µg PM /FF 100 µg AM/PlaceboFF 100 µg PM /Placebo/FF 100 µg AMPlacebo/FF 100 µg AM/FF 100 µg PMPlacebo/FF 100 µg PM /FF 100 µg AM
Started434245
Completed433245
Not completed001000
Withdrew: Met protocol-defined stopping criteria001000

Outcome measures

PrimaryWeighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using site equipment (KoKo Pneumotach Spirometer). Weighted mean FEV1 was calculated using the Day 14 24-hour serial FEV1 measurements taken at 3, 6, 9, 12, 15, 18, 21, and 24 hours post-dose (measured in the evening of Day 15). At each time point, the highest of three technically acceptable measurements was recorded. FEV1 weighted mean was analyzed using a mixed effects analysis of a covariance model with fixed effect terms for treatment and period, participant Baseline, period Baseline, gender, and age as covariates, and participant as a random effect.

Time frame:
24 hours post-PM dose on Day 14 of each treatment period (up to Study Day 105)
Reported as:
Least squares mean · Liters
Weighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period
LitersFF 100 µg AMFF 100 µg PMPlacebo
Weighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period3.303 ± 0.05893.332 ± 0.05843.227 ± 0.0585
Statistical analysis
  • FF 100 µg AM vs Placebo · Median difference (final values): 0.077 · 90% CI 0.001 to 0.152The estimated value represents the difference in Least Squares Means between FF 100 µg AM and Placebo (FF 100 µg AM minus Placebo).
  • FF 100 µg PM vs Placebo · Median difference (final values): 0.105 · 90% CI 0.029 to 0.180The estimated value represents the difference in Least Squares Means between FF 100 µg PM and Placebo (FF 100 µg PM minus Placebo).
  • FF 100 µg AM vs FF 100 µg PM · Median difference (final values): -0.028 · 90% CI -0.102 to 0.045The estimated value represents the difference in Least Squares Means between FF 100 µg AM and FF 100 µg PM (FF 100 µg AM minus FF 100 µg PM).
SecondaryPre-treatment AM and PM Trough FEV1 on Day 14 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using site equipment (KoKo Pneumotach Spirometer). FEV1 PM trough FEV1 values were the values taken pre-treatment on Day 14, and AM trough FEV1 values were the values taken pre-treatment on Day 15 in each treatment period; thus, there is only one value (pre-treatment record) per period for AM and PM trough.

Time frame:
Day 14 of each treatment period (up to Study Day 105)
Reported as:
Least squares mean · Liters
Pre-treatment AM and PM Trough FEV1 on Day 14 of Each Treatment Period
LitersFF 100 µg AMFF 100 µg PMPlacebo
AM Trough FEV13.299 ± 0.07073.359 ± 0.07023.286 ± 0.0703
PM Trough FEV13.236 ± 0.06073.290 ± 0.05983.177 ± 0.0600
SecondaryNumber of Participants With Any Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were collected from the start of dosing with investigational product and until follow-up.

Time frame:
Up to 18 weeks
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE)
ParticipantsFF 100 µg AMFF 100 µg PMPlacebo
Number of Participants With Any Adverse Event (AE)181816
SecondaryPeak Expiratory Flow (PEF)

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. AM and PM pre-treatment PEF was measured throughout the study for the purposes of monitoring participants' asthma stability, and was measured from the start of the Run-in Period until completion of Treatment Period 3 (including during the washout periods), prior to study medication and/or any rescue albuterol/salbutamol inhalation aerosol use. The data collected were only assessed by the Investigator on an individual basis during the study and were not formally summarized or statistically analyzed; consequently, data are not reported.

Time frame:
Up to 18 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Serious adverse event (SAE) and non serious AEs were collected from the start of dosing with investigational product until follow-up (up to 18 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 100 µg AM—0/23 (0%)18/23 (78.3%)
FF 100 µg PM—0/24 (0%)18/24 (75%)
Placebo—0/25 (0%)16/25 (64%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventFF 100 µg AMFF 100 µg PMPlacebo
HeadacheNervous system disorders12/2310/249/25
Upper respiratory tract infectionInfections and infestations6/231/242/25
Viral upper respiratory tract infectionInfections and infestations1/235/242/25
NasopharyngitisInfections and infestations2/231/241/25
NauseaGastrointestinal disorders1/232/241/25
DysmenorrhoeaReproductive system and breast disorders1/232/242/25
GastroenteritisInfections and infestations1/230/242/25
EczemaSkin and subcutaneous tissue disorders1/230/242/25
Respiratory tract infection viralInfections and infestations1/230/240/25
DizzinessNervous system disorders1/231/240/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µg AM/FF 100 µg PM/Placebo
Mean31.7 ± 10.99
Gender
Gender(Participants)FF 100 µg AM/FF 100 µg PM/Placebo
Female15
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF 100 µg AM/FF 100 µg PM/Placebo
African American/African Heritage1
Asian - Central/South Asian Heritage2
Asian - South East Asian Heritage1
White - White/Caucasian/European Heritage21
White - Mixed Race1
Mixed Race2
08

Study locations

1 site
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
09

References and documents

Publications

  • Kempsford RD, Bal J, Baines A, Renaux J, Ravindranath R, Thomas PS. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma. Respir Med. 2016 Mar;112:18-24. doi: 10.1016/j.rmed.2015.12.011. Epub 2016 Jan 12. PubMed 26823210 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2013
First posted
Mar 11, 2013
Start
Mar 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Sep 4, 2014
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01808339
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 11, 2013
Start date
Mar 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Sep 4, 2014
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion